An AI-designed mRNA vaccine successfully treated a Sydney dog with cancer, shrinking his tumor by half and offering hope for future treatments for humans.
Sydney: A trial of a cancer treatment using an mRNA vaccine designed with the help of artificial intelligence (AI) has shown promising results in dogs diagnosed with cancer, raising new hopes for possible applications in humans, according to a report in The Australian newspaper cited by Dawn on Friday.
The case centers on Rosie, an eight-year-old rescue dog who was adopted by Sydney-based technology entrepreneur Paul Conyngham in 2019. In 2024, Rosie was diagnosed with severe mast cell cancer. Initial treatments didn’t bring any improvement, prompting Conyngham to look for another solution. He used chatbots to brainstorm possible treatments, which led him to collaborate with leading medical scientists in search of a cure.
The partnership enabled the development of an experimental mRNA vaccine created using AI technology. Rosie was vaccinated during the 2025 Christmas holidays. One of her tumors reportedly shrunk in half after receiving the drug. The Australian said: “This recovery has surprised researchers at the cutting edge of human cancer treatment.”
Martin Smith, associate professor of computational biology and director of the University’s Ramaciotti Genomics Center, was one of the researchers monitoring the incident. The report says the success of an AI-designed mRNA vaccine in treating Rosie’s cancer has sparked optimism among scientists working on human cancer treatments.
The use of AI in developing personalized medicine, especially for complex diseases such as cancer, is an emerging field. The positive reaction observed in Rosie is being closely monitored by experts who believe it could pave the way for a similar approach in human medicine.
Although the treatment is still experimental and requires further research to consider broader applications, the case highlights the potential of combining AI and mRNA technology in the fight against cancer.
